Release Date: February 1, 2007

Valid Through: January 31, 2008

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM



Fee: There is no fee for this activity

This CME activity is based on the following interactive case study:

Case Study in Refractory Anemia with Excess Blasts
Ravi Vij,  MD, Washington University in St. Louis School of Medicine

Upon completion of this activity, participants should be able to:

• Understand the reduction of mortality risk with the use of DNA hypomethylating agents.
• Discuss the timeline in which responses may occur with the use of azacitidine.
• Compare trilineage responses among therapy with azacitidine and lenalidomide in the treatment of MDS.
• Evaluate complete responses among intensive chemotherapy and DNA hypomethylating agents in the treatment of MDS.

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters

This activity is supported by an unrestricted educational grant from Pharmion.